
ACET Stock Forecast & Price Target
ACET Analyst Ratings
Bulls say
Adicet Bio is a clinical-stage biotechnology company with a positive financial outlook due to its promising pipeline of allogeneic gamma delta T cell therapies, including prulacabtagene leucel and ADI-212, which have shown strong efficacy in treating autoimmune diseases and cancer. Despite competition in the autoimmune landscape, prulacabtagene leucel stands out for its efficacy, safety profile, and allogeneic nature. With a net loss of $21.4MM in 2Q26 and operational runway until 2H27, Adicet remains a buy with a lowered 12-month price target of $27 per share due to increased long-term operating expenses and a higher discount rate. Risks include potential setbacks in clinical development and failure to obtain regulatory approvals, but the potential market value of $306M offers significant upside potential.
Bears say
Adicet Bio is facing numerous risks, including potential delays in clinical trial initiation and the failure of their clinical studies for Lupus/SSc. These setbacks, combined with the possibility of new competitors arising, have raised concerns about the company's future success. Additionally, with no current source of cash flow, Adicet Bio may face the need to raise money in the markets, which could further impact its profitability in the short term.
This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares